TopFunds

Novo Nordisk A/S

NYSE: NVO

Stock price

38.83 USD

(+0%) TODAY

medicineDrug Manufacturers - GeneralInvestable Universe
Financials

all figures in DKK Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
6.8
7.5
7.7
8
8.2
9
10.4
12.2
18.6
22.6
23
13%
02Free cash flow per share
6.2
7.9
6.6
6.6
7.5
6.4
10.3
14.1
15.6
15.6
6.5
0.5%
03Dividends per share
0.4
0.7
0.6
0.6
0.6
0.7
0.7
0.8
1
1.4
1.7
16.8%
04Dividends payout, %
37%
62.8%
49.4%
49.3%
49.8%
47.8%
45.1%
45.6%
38%
43.7%
50.5%
3.2%
PROFIT AND LOSS STATEMENT
05Revenue
107,927
111,780
111,696
111,831
122,021
126,946
140,800
176,954
232,261
290,403
309,064
11.1%
06% Change
-
-
-
-
-
-
-
-
-
-
-
11.1%
07Cost of revenue
(16,188)
(17,183)
(17,632)
(17,617)
(20,088)
(20,932)
(23,658)
(28,448)
(35,765)
(44,522)
(58,788)
13.8%
08Gross profit
91,739
94,597
94,064
94,214
101,933
106,014
117,142
148,506
196,496
245,881
250,276
10.6%
09% Margin
85%
84.6%
84.2%
84.3%
83.5%
83.5%
83.2%
83.9%
84.6%
84.7%
81%
83.9% A
10Operating expenses
(42,295)
(46,165)
(45,097)
(46,966)
(49,450)
(51,888)
(58,498)
(73,697)
(93,922)
(117,542)
(122,618)
11.2%
11% of Revenue
(39.2)%
(41.3)%
(40.4)%
(42)%
(40.5)%
(40.9)%
(41.6)%
(41.7)%
(40.4)%
(40.5)%
(39.7)%
(40.7)% A
12Operating Income
49,444
48,432
48,967
47,248
52,483
54,126
58,644
74,809
102,574
128,339
127,658
10%
13Income tax expense
(8,623)
(9,873)
(10,550)
(8,987)
(9,602)
(10,992)
(11,323)
(13,537)
(20,991)
(26,203)
(28,106)
12.5%
14Net Income
34,860
37,925
38,130
38,628
38,951
42,138
47,757
55,525
83,683
100,988
102,434
11.4%
15% Margin
32.3%
33.9%
34.1%
34.5%
31.9%
33.2%
33.9%
31.4%
36%
34.8%
33.1%
33.6% A
16Shares Outstanding
5,157
5,070
4,956
4,849
4,757
4,680
4,606
4,545
4,495
4,463
4,448
(1.5)%
17EPS Basic
6.8
7.5
7.7
8
8.2
9
10.4
12.3
18.7
22.7
23.1
13%
18EPS Diluted
6.8
7.5
7.7
8
8.2
9
10.4
12.2
18.6
22.6
23
13%
19EBITDA
46,509
51,056
51,952
51,625
54,434
59,273
65,394
76,802
114,629
147,938
156,729
12.9%
% Margin
43.1%
45.7%
46.5%
46.2%
44.6%
46.7%
46.4%
43.4%
49.4%
50.9%
50.7%
46.7% A
20Net Interest Income (expense)
(11)
(13)
(21)
(34)
(155)
(53)
(58)
(139)
527
198
(2,938)
74.9%
21Net Debt / EBITDA
(0.3)
(0.4)
(0.3)
(0.3)
(0.2)
-
0.2
0.2
0.1
0.6
0.7
-
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
16,923
18,690
18,852
15,638
15,475
12,757
10,720
12,653
14,392
15,655
26,464
4.6%
23Short-term investments
3,542
2,009
-
-
-
-
6,765
10,921
15,838
10,653
498
(17.8)%
24Accounts receivable
17,742
24,197
23,551
26,889
29,152
32,184
46,799
57,505
75,261
87,414
75,698
15.6%
25Other current assets
6,432
529
2,304
204
188
2,332
1,690
2,727
2,344
6,326
20,171
12.1%
26Inventory
12,758
14,341
15,373
16,336
17,641
18,536
19,621
24,388
31,811
40,849
49,623
14.6%
27Total Current Assets
55,140
59,766
60,080
59,067
62,456
65,809
85,595
108,194
139,646
160,897
172,453
12.1%
Non-Current Assets
28Net property, plant & equipment
25,545
30,179
35,247
41,891
50,551
50,269
55,362
66,671
90,961
162,488
208,378
23.4%
29Long-term investments
2,150
2,197
1,762
1,773
1,808
1,648
1,441
1,343
1,663
2,677
2,507
1.6%
30Other non-current assets
8,964
5,397
5,266
8,038
10,797
27,196
52,110
65,049
82,216
139,733
159,564
33.4%
31Total Non-Current Assets
36,659
37,773
42,275
51,702
63,156
79,113
108,913
133,063
174,840
304,898
370,449
26%
Total Assets
91,799
97,539
102,355
110,769
125,612
144,922
194,508
241,257
314,486
465,795
542,902
19.5%
LIABILITIES
Current Liabilities
32Accounts payable
4,927
6,011
5,610
6,756
6,358
5,717
8,870
15,587
25,606
28,846
19,758
14.9%
33Short-term debt
1,073
229
1,694
515
1,474
7,459
13,684
1,466
6,478
13,113
12,017
27.3%
34Other current liabilities
34,873
41,196
39,752
46,893
51,151
57,097
76,962
103,887
137,571
175,569
183,886
18.1%
35Total Current Liabilities
40,873
47,436
47,056
54,164
58,983
70,273
99,516
120,940
169,655
217,528
215,661
18.1%
Non-Current Liabilities
36Long-term debt
-
-
-
-
3,009
2,897
12,961
24,318
20,528
89,674
118,941
-
37Other non-current liabilities
3,957
4,834
5,484
4,766
6,027
8,427
11,285
12,513
17,742
15,107
14,253
13.7%
38Total Non-Current Liabilities
3,957
4,834
5,484
4,766
9,036
11,324
24,246
36,831
38,270
104,781
133,194
42.1%
39Total Liabilities
44,830
52,270
52,540
58,930
68,019
81,597
123,762
157,771
207,925
322,309
348,855
22.8%
SHAREHOLDERS` EQUITY
40Common stock
520
510
500
490
480
470
462
456
451
446
446
(1.5)%
41Retained earnings / (deficit)
46,816
46,111
48,977
53,406
57,817
63,774
72,004
80,587
104,839
144,448
195,298
15.4%
42Accumulated other comprehensive income / (loss)
(357)
(1,343)
349
(2,046)
(694)
(911)
(1,714)
2,449
1,276
(1,406)
(1,695)
16.9%
43Noncontrolling interests
-
-
-
-
-
-
-
-
-
-
-
-
44Total shareholders' equity
46,969
45,269
49,815
51,839
57,593
63,325
70,746
83,486
106,561
143,486
194,047
15.2%
45Total Liabilities and shareholders' Equity
91,799
97,539
102,355
110,769
125,612
144,922
194,508
241,257
314,486
465,795
542,902
19.5%
46Total Debt
1,073
229
1,694
515
4,483
10,356
26,645
25,784
27,006
102,787
130,958
61.7%
47Net Debt
(15,850)
(18,461)
(17,158)
(15,123)
(10,992)
(2,401)
15,925
13,131
12,614
87,132
104,494
-
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
34,860
37,925
38,130
38,628
38,951
42,138
47,757
55,525
83,683
100,988
102,434
11.4%
49Depreciation & amortization
2,959
3,193
3,182
3,925
5,661
5,753
6,025
7,362
9,413
19,107
21,982
22.2%
50Share-based compensation expense
442
368
292
414
363
823
1,040
1,539
2,149
2,289
-
-
51Changes in working capital and other assets
26
6,828
(436)
1,649
1,807
3,237
178
14,461
13,663
(1,416)
(5,314)
-
52Net cash flows from operating activities
38,287
48,314
41,168
44,616
46,782
51,951
55,000
78,887
108,908
120,968
119,102
12%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(6,406)
(8,267)
(8,648)
(12,410)
(11,231)
(22,081)
(7,385)
(12,146)
(25,806)
(47,164)
(60,140)
25.1%
54Purchases of investments / marketable securities
(3,542)
(643)
(40)
(248)
(350)
16,256
(7,113)
(9,735)
(13,289)
(19,814)
(723)
(14.7)%
55Proceeds from maturities of marketable securities
1,532
2,087
2,082
178
148
12
1,172
6,645
8,293
24,391
10,674
21.4%
56Other investing activities
2,318
33
35
400
(76)
(16,623)
(18,279)
(9,682)
(13,090)
(86,308)
(28,969)
-
57Net cash flows from investing activities
(6,098)
(6,790)
(6,571)
(12,080)
(11,509)
(22,436)
(31,605)
(24,918)
(43,892)
(128,895)
(79,158)
29.2%
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
(17,196)
(15,057)
(16,845)
(15,567)
(15,334)
(16,855)
(19,447)
(24,086)
(29,924)
(20,181)
(1,388)
(22.3)%
59Dividends paid, net
(12,905)
(23,830)
(18,844)
(19,048)
(19,409)
(20,121)
(21,517)
(25,303)
(31,767)
(44,140)
(51,763)
14.9%
60Debt issuance (repayments), net
-
-
-
94
(741)
4,732
15,471
(2,408)
(1,467)
73,056
24,743
-
61Other financing activities
-
-
-
-
-
-
-
-
-
-
-
-
62Net cash flows from financing activities
(30,101)
(38,887)
(35,689)
(34,521)
(35,484)
(32,244)
(25,493)
(51,797)
(63,158)
8,735
(28,408)
(0.6)%
63Increase (decrease) in cash and cash equivalents
2,174
2,611
(1,303)
(1,529)
(218)
(3,185)
(1,507)
1,934
1,739
1,263
10,809
17.4%
64Cash and equivalents, ending balance
15,850
18,461
17,158
15,629
15,411
12,226
10,719
12,653
14,392
15,655
26,464
5.3%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
31,881
40,047
32,520
32,206
35,551
29,870
47,615
66,741
83,102
73,804
58,962
6.3%

Novo Nordisk A/S (NVO) financial statements and performance

Explore Novo Nordisk A/S (NVO) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.